Medical Condition News

RSS

Dysautonomia linked to CKD: Study

Individuals with a high resting heart rate and a low beat-to-beat heart rate variability have an increased risk of developing kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology. The findings suggest that the behavior of the autonomic nervous system may be a sentinel marker for late development of certain cases of kidney disease.

9 Jul 2010

Patients enrolled in CLARITY-AF study

Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announces that more than 10 patients have now been enrolled in the CLARITY-study, comparing the efficacy, safety and efficiency of CARTO 3 System guided radiofrequency ablation using the NAVISTAR THERMOCOOL catheter versus fluoroscopy guided radiofrequency ablation using the Pulmonary Vein Ablation catheter (Ablation Frontiers, Medtronic) in patients with paroxysmal atrial fibrillation.

9 Jul 2010

New rules pave way for veterans' PTSD disability claims

The New York Times: Veterans with post-traumatic stress disorder who are seeking disability benefits will get a break when new rules go into effect as early as next week.

9 Jul 2010

Study finds EUS associated with improved outcomes in patients with localized pancreatic cancer

A new study has found that endoscopic ultrasound (EUS) is associated with improved outcomes in patients with localized pancreatic cancer, possibly due to the detection of earlier cancers and improved stage-appropriate management, including more selective performance of curative intent surgery. This is the first study to analyze a large population-based cancer registry and demonstrate that EUS evaluation is associated with improved pancreatic cancer survival.

9 Jul 2010

Research finding uncovers alternative treatments for people with hereditary colorectal cancer

By solving the three-dimensional structure of a protein involved in repairing DNA errors, a group of McMaster University researchers have revealed new avenues to develop assessment tools and alternative treatments for people living with hereditary colorectal cancers.

9 Jul 2010

IRIC scientists identify vitamin B3 as potential antifungal treatment

A team of scientists from the Institute for Research in Immunology and Cancer (IRIC) of the University of Montreal have identified vitamin B3 as a potential antifungal treatment. Led by IRIC Principal Investigators Martine Raymond, Alain Verreault and Pierre Thibault, in collaboration with Alaka Mullick, from the Biotechnology Research Institute of the National Research Council Canada, the study is the subject of a recent article in Nature Medicine.

9 Jul 2010

Emotional well-being predicts adolescents' physical health: Study

Happier youths are also healthier youths, according to Emily Shaffer-Hudkins and her team, from the University of South Florida in the US. Adolescents' positive emotions and moods, as well as their satisfaction with life, could be more important than their anxiety or depression levels for predicting their physical health, they argue.

9 Jul 2010

Australian, Vietnamese researchers develop simple tool for identifying individuals at high risk of Type 2 diabetes

Australian and Vietnamese researchers have estimated the current prevalence of Type 2 diabetes in Vietnam, and have developed a simple tool for identifying individuals at high risk.

9 Jul 2010

Jasmine can be used instead of sleeping pills or mood enhancers: Study

Instead of a sleeping pill or a mood enhancer, a nose full of jasmine from Gardenia jasminoides could also help: in collaboration with Dr. Olga Sergeeva and Prof. Helmut Hass from the Heinrich Heine University in Düsseldorf, researchers from Bochum led by Prof. Dr. Dr. Dr. Hanns Hatt have discovered that the two fragrances Vertacetal-coeur (VC) and the chemical variation (PI24513) have the same molecular mechanism of action and are as strong as the commonly prescribed barbiturates or propofol.

9 Jul 2010

NeuroPace submits PMA to FDA for world's first responsive neurostimulation system

NeuroPace, Inc. today announced that it has submitted its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its RNS® System, a novel investigational device that utilizes responsive neurostimulation to monitor and interrupt abnormal electrical activity in the brain before seizures occur. The PMA application is for an indication to treat people with medically refractory partial onset epilepsy originating from one or two locations in the brain.

9 Jul 2010

FDA approves Roxane's Naratriptan Tablets ANDA

Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Naratriptan Tablets USP, 1mg and 2.5mg by the U.S. Food and Drug Administration. The product is available in bottles of 9 for immediate shipment to wholesalers and pharmacies nationwide.

9 Jul 2010

Qualaquin for treatment of night time leg cramps leads to serious side effects, FDA warns

The U.S. Food and Drug Administration today warned that the unapproved use of the malaria drug Qualaquin (quinine sulfate) to treat night time leg cramps has resulted in serious side effects and prompted the manufacturer to develop a risk management plan aimed at educating health care professionals and patients about the potential risks.

9 Jul 2010

BioCurex reports first set of results supporting RECAF blood test for monitoring cancer therapy

BioCurex Inc. today announced its first set of results supporting the use of the BioCurex RECAF blood test to monitor cancer therapy. The test included samples from 27 human patients with early stages of breast cancer that were tested before and after surgery. As a control, 15 samples from healthy individuals were also tested.

9 Jul 2010

Bayer HealthCare to present BAY86-6150 rFVIIa Phase I clinical data at XXIX WFH International Congress

Phase I clinical data for BAY86-6150, a novel recombinant factor VIIa protein (rFVIIa) being developed by Bayer HealthCare, will be presented at the XXIX International Congress of the World Federation of Hemophilia (WFH) to be held in Buenos Aires, Argentina from Saturday, July 10-Wednesday, July 14.

9 Jul 2010

pSivida submits MAA for Iluvien to UK MHRA

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) for Iluvien®.

8 Jul 2010

Study demonstrates causal relationship between onset of Creutzfeldt-Jakob disease and general surgery

A new study spearheaded by Spanish scientists demonstrates a causal relationship between the onset of Creutzfeldt-Jakob disease (CJD), caused by a protein called a prion, and general surgery. CJD manifests itself in hereditary acquired; and sporadic forms, or for unknown reasons, which accounts for the majority of cases.

8 Jul 2010

Rockwell Medical completes End of Phase II meeting with FDA regarding SFP

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that it has successfully completed an End of Phase II meeting with the U.S. Food and Drug Administration regarding the Company's lead drug candidate Soluble Ferric Pyrophosphate, a novel continuous iron-replacement therapy designed to treat iron deficiency anemia in hemodialysis patients.

8 Jul 2010

Fibrocell Science completes enrollment in azficel-T histology study

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the completion of enrollment of and first treatment visits for participants in its histology study (IT-H-001) of azficel-T. An autologous cell therapy, azficel-T is currently under review by the U.S. Food and Drug Administration for the treatment of moderate to severe nasolabial fold wrinkles.

8 Jul 2010

First patient enrolled in Boston Scientific's MultiSENSE clinical trial

Boston Scientific Corporation today announced enrollment of the first patient in its MultiSENSE clinical trial. The trial is designed to evaluate multiple physiologic sensors in the Company's COGNIS cardiac resynchronization therapy defibrillators. Boston Scientific plans to use the trial data to help develop a clinical alert that identifies the early onset of worsening heart failure.

8 Jul 2010

Alimera Sciences submits MAA for Iluvien to MHRA

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals has submitted a Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency in the United Kingdom for Iluvien (fluocinolone acetonide intravitreal insert).

8 Jul 2010

Medical Condition News

Dysautonomia linked to CKD: Study

Patients enrolled in CLARITY-AF study

New rules pave way for veterans' PTSD disability claims

Study finds EUS associated with improved outcomes in patients with localized pancreatic cancer

Research finding uncovers alternative treatments for people with hereditary colorectal cancer

IRIC scientists identify vitamin B3 as potential antifungal treatment

Emotional well-being predicts adolescents' physical health: Study

Australian, Vietnamese researchers develop simple tool for identifying individuals at high risk of Type 2 diabetes

Jasmine can be used instead of sleeping pills or mood enhancers: Study

NeuroPace submits PMA to FDA for world's first responsive neurostimulation system

FDA approves Roxane's Naratriptan Tablets ANDA

Qualaquin for treatment of night time leg cramps leads to serious side effects, FDA warns

BioCurex reports first set of results supporting RECAF blood test for monitoring cancer therapy

Bayer HealthCare to present BAY86-6150 rFVIIa Phase I clinical data at XXIX WFH International Congress

pSivida submits MAA for Iluvien to UK MHRA

Study demonstrates causal relationship between onset of Creutzfeldt-Jakob disease and general surgery

Rockwell Medical completes End of Phase II meeting with FDA regarding SFP

Fibrocell Science completes enrollment in azficel-T histology study

First patient enrolled in Boston Scientific's MultiSENSE clinical trial

Alimera Sciences submits MAA for Iluvien to MHRA

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News